Persistent infection with the hepatitis B virus leads to liver cirrhosis and hepatocel- 
mortality of these diseases is serious, with approximately 600 000 HBV-related deaths estimated annually and 73% of liver cancer deaths attributed to hepatitis viruses. 3 Approximately 8%-20% of patients with chronic hepatitis B (CHB) develop liver cirrhosis, and among these, the risk of hepatocellular carcinoma (HCC) is 2%-5%. 4 HBV infection is responsible for 50%-80% of HCC cases. Chronic liver injury leads to liver cell death and regeneration of parenchymal cells. 5 However, persistent liver injury can lead to failure of regeneration and the replacement of hepatocytes by extracellular matrix (ECM) mainly derived from hepatic stellate cells. 6, 7 Therefore, a better understanding of the mechanisms underlying HBV-related liver injury and the development of early detection methods to prevent progression to cirrhosis and HCC are essential for the prevention and treatment of liver diseases.
MicroRNAs (miRNAs) are small endogenous non-coding RNAs that modulate gene expression by binding to the 3 0 -untranslated region (3 0 -UTR) of target mRNAs to inhibit translation or induce mRNA degradation. 8 miRNAs are involved in many physiological processes including cell proliferation, differentiation and apoptosis, and aberrant expression of miRNAs is associated with several diseases. 9 Certain miRNAs play a role in the maintenance of hepatocyte function, such as miR-122a, which promotes the replication of the hepatitis C virus in hepatocytes, and miR-150 and miR-194, which inhibit hepatic stellate cell activation and extracellular matrix production associated with liver fibrosis. [10] [11] [12] miRNAs such as miR-122 and miR-192 are overexpressed in the livers of mice exposed to druginduced liver injury in a pattern mimicking that of serum aminotransferase levels and the histopathology of liver degeneration. The same miRNAs are overexpressed in humans with acetaminophen-induced acute liver injury, suggesting their value as markers of liver damage. 13, 14 Activins are secreted polypeptides that belong to the transforming growth factor beta (TGFb) superfamily, which plays a role in the regulation of cell proliferation, apoptosis, inflammation and differentiation in many cell types and organs including the liver. 15 Activins are homo-or heterodimers of different b subunits that either dimerize with another b subunit to form activins or dimerize with a single a subunit to form inhibins. 15, 16 Activin A, which functions as an inhibitor of liver growth, signals through two types of transmembrane serine threonine kinase receptors, binding first to type II activin receptors, which recruit and phosphorylate type I receptors. 17, 18 There are two type II receptors, ActR-II or ACVR22 and ActR-IIB or ACVR2B. Similar to other TGFb family receptors, activin A receptors recruit Smads 2 and 3 to transduce signals to the nucleus, although the existence of Smad-independent signalling pathways has been suggested. 15, 19, 20 In a previous study, we identified a plasma miRNA panel for the diagnosis of hepatitis B-related HCC in a cohort of 934 patients with CHB, cirrhosis and HBV-related HCC using microarray technology. 21 In this study, we expanded this work by exploring the role and mechanisms of miR-194, one of six differentially expressed miRNAs in CHB, and its target ACVR2B in liver injury and regeneration associated with CHB.
| MATERIALS AND METHODS

| Microarray analysis and quantitative reversetranscriptase PCR (qRT-PCR) validation
This study was approved by the local institutional review boards and informed consent was obtained from all study participants. Between   August 2008 and June 2012, 231 participants (91 healthy and 140 CHB) who met the eligibility criteria (Table S1) were recruited from Shanghai Zhongshan Hospital, Huashan Hospital and Public Health Clinical Center. The 231 blood samples were allocated to two phases in chronological order ( Figure S1A ). There was no sample overlapping among the two phases. Table S2 shows the clinical characteristics of the study subjects. We used human miRNA microarray 2.0 from Agilent Technologies (Santa Clara, CA) to identify candidate miRNAs in 55 plasma samples (33 healthy and 22 CHB) as described in our previous study. 21 The details of microarray hybridization are described in Appendix S1.
For testing of candidate miRNAs identified on microarrays, qRT-PCR was performed using Taqman microRNA assays (Applied Biosystems, FosterCity, CA, USA). The assay was performed on plasma samples of 118 CHB patients and 58 healthy individuals for 9 candidate miRNAs (miR-122, miR-122*, miR-148a, miR-192, miR-194, miR-23b, miR-215, miR-27b, and miR-29b) that met the defined criteria ( Figure S1B ). The expression levels of miRNAs were normalized to miR-1228 levels 21, 22 and calculated using the 2 ÀMCt method. All assays were performed in triplicate.
| Histological examination of liver biopsy specimens
Sixty-six CHB patients suspected to have HBV-related liver damage underwent liver biopsy. The biopsy specimens were fixed with 10%
formalin, routinely embedded in paraffin, and tissue sections were stained with haematoxylin and eosin (H&E). The H&E sections with at least six portal tracts were blindly and independently assessed by three experienced pathologists, and the severity of chronic liver damage was evaluated according to the Scheuer classification system as follows 23 : G0, none; G1, inflammation but no necrosis; G2, focal necrosis or acidophil bodies; G3, severe focal cell damage; and G4, damage including bridging necrosis.
| Animals and operative procedure
Healthy male C57BL/6J mice (n = 36, purchased from Shanghai under isoflurane anaesthesia as previously described. 24 Mice were killed and the remnant liver tissues were collected at 1, 3, 5, 7, and 14 days after surgery. One part was frozen in liquid nitrogen and stored at À80°C; the other part was fixed in 4% paraformaldehyde.
Liver and body weight were recorded.
| Immunohistochemical staining
The fixed liver tissues were embedded and 5 lm thick sections were prepared. The slides were stained with anti-Ki-67, anti-proliferating cell nuclear antigen (PCNA), anti-cyclin D1 and anti-ACVR2B
(Abcam, Cambridge, UK) and visualized with DAB (Sigma, St. Louis, MO, USA) followed by counterstaining with H&E (Sigma).
| Cell culture and treatment
Human HL7702 normal liver cells were maintained in RPMI-1640 medium (Gibco, USA) supplemented with 10% foetal bovine serum (Gibco) and 1% penicillin-streptomycin (Gibco) at 37°C in 5% CO 2 . 
| Luciferase assay
The 3 instructions. Cells were harvested at 24 hours after transfection, and luciferase activity was measured using a dual-luciferase reporter assay system (Promega).
| qRT-PCR
Total RNA was isolated from prepared mouse liver samples or transfected cells using the Trizol reagent (Invitrogen, CA, USA). cDNA was synthesized using Taqman RT reagents (Applied Biosystems, CA, USA) following the manufacturer's protocol. qRT-PCR was performed using a standard SYBR green PCR kit (Qiagen, Hilden,Germany), and PCR-specific amplification was performed using the Applied Biosystems (ABI7300) real-time PCR machine. The relative expression of target genes was calculated with the 2 ÀMMCt method. miR-194 expression was normalized to U6 and ACVR2B to b-actin. Primers are listed as follows: miR-194, 5 0 -CGA TCT CTC ATG TAA CAG
| Western blot analysis
Tissues and cells were lysed in RIPA lysis buffer (Santa Cruz Biotechnology, CA, USA). The lysates were sonicated and centrifuged at 11 750 g at 4°C for 10 minutes. Equal amounts of protein were separated using 10% sodium dodecyl sulphate-polyacrylamide gel electrophoresis and transferred to nitrocellulose membranes. For immunodetection, membranes were incubated with primary antibodies against ACVR2B, p53, p-Smad2, p-Smad3, and Smad2/3 (Abcam).
The immunoblots were developed using horseradish peroxidase (HRP)-coupled secondary antibodies (Abcam) followed by detection with an ECL kit (Pierce Biotechnology, Rockford, USA). b-actin was used as a control.
| MTT cell proliferation assay
Cell proliferation rates were measured using 3-(4,5-dimethylthiazol- 3 | RESULTS
| Statistical analysis
| miR-194 is up-regulated in correlation with increased liver damage in CHB patients
Hierarchical clustering analysis of microarray data showed that 33/ 33 healthy individuals and 21/22 CHB patients were correctly classified using differentially expressed miRNAs ( Figure S1C ). Candidate miRNAs were selected from the microarray platform using two eligibility criteria: (i) corrected P ≤ .0001 with fold change > 10, and
(ii) normalized signal value ≥30 in the plasma of CHB patients. Nine candidate miRNAs met the criteria and were validated in an independent cohort of 176 plasma samples including 118 CHB patients and 58 healthy individuals using qRT-PCR. Of the nine candidates, seven plasma miRNAs (miR-122, miR-148a, miR-192, miR-194, miR-215, miR-27b, and miR-29b) showed significantly higher expression in CHB patients than in healthy individuals (Table S3 ).
According to the Scheuer Classification System of histological grades of liver damage, G0 and G1 patients had no necrosis, whereas G2, G3, and G4 patients showed necrosis. Therefore, CHB patients were divided into two groups, G0-1 without significant liver damage and G2-4 with significant liver damage. Analysis of the 118 CHB patients who underwent liver biopsy showed higher expression levels of miR-122, miR-148a, miR-192, miR-194, miR-215, and miR27b in CHB patients with G2-4 than in CHB patients with G0-1 (fold changes: 3.1, 3.2, 2.6, 2.6, 3.3, and 1.9, respectively; Table 1), whereas there was no statistically significant difference between G0
and G1, or G2 and G3/4. Further analysis of miR-194 expression in plasma and tissues of CHB patients with different histological grades of liver damage also showed higher expression levels in the G2 and G3 groups than in the G0 and G1 groups ( Figure 1A and B) . 
| miR-194 is induced in response to partial hepatectomy
To determine the impact of miR-194 on liver hepatocyte growth, mice were subjected to 2/3 partial hepatectomy (PH). As shown in Figure S2B ). These results were confirmed using the dual-luciferase reporter assay system, which showed that miR-194 overexpression and silencing significantly inhibited and promoted luciferase reporter activity, respectively, in the wild-type but not the mutant construct ( Figure 3D and E). Correlation analysis showed a significant negative correlation between the mRNA expression of miR-194 and ACVR2B in mouse liver tissues ( Figure 3F ).
| miR-194 promotes cell proliferation and inhibits apoptosis in human HL7702 liver cells
The The miRNA selected for study is shown in bold.
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| 4537 inhibition had the opposite effect ( Figure 4A ). Flow cytometry showed that miR-194 overexpression accelerated cell cycle G1 to S phase transition ( Figure 4B ) and significantly inhibited cell apoptosis ( Figure 4C ), whereas miR-194 knockdown had the opposite effects.
| miR-194 promotes hepatocyte proliferation and inhibits apoptosis by targeting ACVR2B
The mechanism underlying the effect of miR-194 on hepatocyte and has been suggested to play a role in hepatic stellate cell activation during fibrogenesis. 12 The fact that miR-194 is expressed in hepatic epithelial cells, whereas it is not detected in mesenchymal cells, suggests that it is involved in epithelial-mesenchymal transition F I G U R E 2 miR-194 was up-regulated in a mouse model of partial hepatectomy (PH). A, Recovery of functional liver mass after PH (normalized liver to body weight ratio). Data represent the mean AE SEM with n = 6 per group. B, The expression of miR-194 in mouse liver tissues was detected by qRT-PCR. C and D, The mRNA and protein expression levels of ACVR2B were determined by qRT-PCR and Western blotting, respectively. *P < .05, **P < .01. (E) Liver immunohistochemical staining for Ki-67, PCNA, cyclin D1, and ACVR2B. Original magnification, 200 9
and plays an antimetastatic role in HCC. 27 miR-194 expression in the liver is modulated by transcription factor 1 or hepatocyte nuclear factor 1a (HNF1a) 28 and HNF4a, 29 The liver is characterized by a high regenerative capacity in the presence of damaging agents. 39 The response of the liver to injury includes the activation of non-parenchymal cells and the production of several factors, leading to the proliferation of hepatocytes and the restoration of tissue architecture via fibrosis. [40] [41] [42] The TGFb signalling pathway plays an important role in liver homeostasis and in regulating hepatocyte apoptosis. Liver regeneration, which involves signalling between non-parenchymal cells and hepatocytes, is divided into phases including the priming, proliferative, remodelling, and terminating phases, and activin A and its receptors are involved in the termination phase. 43 ACVR2B is down-regulated during liver regeneration after PH, and ectopic expression of ACVR2B induces apoptosis in hepatoma cells. [44] [45] [46] Inactivating mutations of activin receptors were reported in colon, pancreatic, and prostate cancer. [47] [48] [49] 
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F I G U R E 5 ACVR2B reversed the effect of miR-194 on hepatic cell growth and apoptosis. A and B, The mRNA and protein expression levels of ACVR2B were determined by qRT-PCR and western blotting, respectively. C, Cell proliferation was assessed using the MTT assay in HL7702 cells transduced with ACVR2B, miR-194, miR-194 + ACVR2B, or negative control. D and E, Cell cycle distribution and cell apoptosis were analysed by flow cytometry. F, Expression levels of phosphorylated Smad2/3 were determined by western blotting. n = 3. *P < .05, **P < .01 vs control; #P < .05, ##P < .01 vs miR-194
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